Last reviewed · How we verify
bupivacaine(intraperitoneally)
Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia.
Bupivacaine blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials to produce local anesthesia. Used for Local anesthesia and analgesia for intra-abdominal procedures via intraperitoneal administration.
At a glance
| Generic name | bupivacaine(intraperitoneally) |
|---|---|
| Sponsor | Ain Shams University |
| Drug class | Local anesthetic (amide class) |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Anesthesia / Pain Management |
| Phase | FDA-approved |
Mechanism of action
As a long-acting amide local anesthetic, bupivacaine reversibly inhibits sodium influx through voltage-gated sodium channels in nerve fibers, thereby stabilizing the neuronal membrane and preventing depolarization. When administered intraperitoneally, it anesthetizes visceral nerves and peritoneal tissues to reduce pain during or after abdominal procedures. The intraperitoneally route allows direct contact with peritoneal surfaces and visceral innervation.
Approved indications
- Local anesthesia and analgesia for intra-abdominal procedures via intraperitoneal administration
Common side effects
- Systemic toxicity (CNS effects: tremor, seizures)
- Cardiovascular effects (hypotension, arrhythmias)
- Local tissue irritation or peritoneal inflammation
- Allergic reactions
Key clinical trials
- Comparison Of Clinical Outcomes of Intraperitoneal Bupivacaine Instillation Versus Placebo as Preemptive Analgesia in Patients Undergoing Open Appendectomy (PHASE1)
- Effect of Intraperitoneal Dexmedetomidine Added to Bupivacaine 0.25% Versus Bupivacaine Alone on Postoperative Analgesia in Patients Undergoing Laparoscopic Cholecystectomy (NA)
- Peritoneal Lavage Using Saline or Saline With Ondansetron for Pain Control After Laparoscopic Cholecystectomy (PHASE4)
- Intrathecal Morphine Versus Trocar-Site and Intraperitoneal Bupivacaine for Quality of Recovery After Laparoscopic Hysterectomy (NA)
- Efficacy of Preventive Ketamine on Postoperative Pain (PHASE4)
- Retrolaminar Block Versus Intraperitoneal Block for Laparoscopic Cholecystectomy (NA)
- Efficacy of Adding Dexmedetomidine Versus Ibuprofen as an Adjuvant to Intraperitoneal Bupivacaine for Pain Control After Laparoscopic Gynecological Procedures (PHASE2, PHASE3)
- Intraperitoneal Dexmedetomidine Versus Ketamine With Bupivacaine For Postoperative Analgesia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- bupivacaine(intraperitoneally) CI brief — competitive landscape report
- bupivacaine(intraperitoneally) updates RSS · CI watch RSS
- Ain Shams University portfolio CI